A Phase 2 interventional study of JZP-110 and Placebo in Excessive Sleepiness and Parkinson Disease, sponsored by Jazz Pharmaceuticals. Completed at 25 sites in United States. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-09.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing solriamfetol in Disorders of Excessive Somnolence — 3 open to participants now, 3 under way, 2 of them phase 3. solriamfetol · Disorders of Excessive Somnolence.
Among the 12 studies testing solriamfetol in Disorders of Excessive Somnolence, this one is the 7th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 3rd registered.
196 studies on the registry are indexed under Disorders of Excessive Somnolence; 34 are open to participants now.
Browse Disorders of Excessive Somnolence studies →3 of the 12 studies testing solriamfetol in Disorders of Excessive Somnolence are open now, in 2 countries. Recruiting first, the newest first:
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Axsome Therapeutics, Inc. · Sites in United States, Canada
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 18–60
By country, each count listing its studies:
solriamfetol: first FDA approval 2019 (SUNOSI), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 30 Disorders of Excessive Somnolence studies recruiting now, 12 (40%) set no upper age limit and 17 (57%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is below the median of 86 across 158 interventional studies indexed under Disorders of Excessive Somnolence.
Median enrollment 75 across the 12 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 6 studies filed under Disorders of Excessive Somnolence — fewer than ten, so there is no comparison to draw.
2 of the studies testing solriamfetol in Disorders of Excessive Somnolence that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06170970Johns Hopkins UniversitySolriamfetol for the Treatment of Multiple Sclerosis Fatigue | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing solriamfetol in Disorders of Excessive Somnolence, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JZP-110 and Placebo
Drug: JZP-110 · Other: Placebo
JZP-110 and Placebo
Drug: JZP-110 · Other: Placebo
Placebo
Other: Placebo
75 mg, 150 mg, 300 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation
Time frame: Up to Day 35
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score
Change from Baseline ESS defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions, asking subjects how likely they would be to doze off or fall asleep in different situations. Responses range from 0 = would never doze to 3 = high chance of dozing. Higher scores represent greater severity of excessive sleepiness. The total score ranges from 0 - 24, with higher scores representing greater severity of excessive sleepiness.
Time frame: Baseline to Weeks 1, 2, 3, and 4
Change From Baseline in the Mean Sleep Latency Time (in Minutes) on the Maintenance of Wakefulness Test (MWT)
Change from Baseline mean sleep latency (in minutes) on the MWT defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The MWT is the standard objective measure of an individual's ability to remain awake during the daytime in a darkened, quiet environment. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicated greater ability to stay awake.
Time frame: Baseline to Weeks 1, 2, 3, and 4
| Milestone | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C |
|---|---|---|---|
| Started | 28 | 28 | 10 |
| Completed | 27 | 26 | 9 |
| Not completed | 1 | 2 | 1 |
| Participants | JZP-110 75mg | JZP-110 150mg | JZP-110 300mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation | 1 | 2 | 0 | 0 |
Change from Baseline ESS defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions, asking subjects how likely they would be to doze off or fall asleep in different situations. Responses range from 0 = would never doze to 3 = high chance of dozing. Higher scores represent greater severity of excessive sleepiness. The total score ranges from 0 - 24, with higher scores representing greater severity of excessive sleepiness.
| score on a scale | JZP-110 75mg | JZP-110 150mg | JZP-110 300mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score | -4.82 ± 0.67 | -5.04 ± 0.70 | -5.72 ± 0.68 | -4.78 ± 0.58 |
Change from Baseline mean sleep latency (in minutes) on the MWT defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4). The MWT is the standard objective measure of an individual's ability to remain awake during the daytime in a darkened, quiet environment. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicated greater ability to stay awake.
| minutes | JZP-110 75mg | JZP-110 150mg | JZP-110 300mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in the Mean Sleep Latency Time (in Minutes) on the Maintenance of Wakefulness Test (MWT) | 0.4289 ± 2.1254 | 2.6721 ± 2.1961 | 6.8133 ± 2.1351 | 1.7670 ± 1.8479 |
Collected over Up to Day 35. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JZP-110 75 mg | 0/56 (0%) | 0/56 (0%) | 4/56 (7.1%) |
| JZP-110 150 mg | 0/55 (0%) | 0/55 (0%) | 5/55 (9.1%) |
| JZP-110 300 mg | 0/54 (0%) | 1/54 (1.9%) | 4/54 (7.4%) |
| Placebo | 0/64 (0%) | 0/64 (0%) | 0/64 (0%) |
| Event | JZP-110 75 mg | JZP-110 150 mg | JZP-110 300 mg | Placebo |
|---|---|---|---|---|
| HaematuriaRenal and urinary disorders | 0/56 | 0/55 | 1/54 | 0/64 |
| Event | JZP-110 75 mg | JZP-110 150 mg | JZP-110 300 mg | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/56 | 2/55 | 3/54 | 0/64 |
| HeadacheNervous system disorders | 1/56 | 3/55 | 2/54 | 0/64 |
| DizzinessNervous system disorders | 3/56 | 0/55 | 1/54 | 0/64 |
| Age, Continuous(years) | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Total |
|---|---|---|---|---|
| Mean | 65.9 ± 7.64 | 62.9 ± 8.75 | 65.4 ± 9.75 | 64.6 ± 8.45 |
| Sex: Female, Male(Participants) | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Total |
|---|---|---|---|---|
| Female | 10 | 6 | 5 | 21 |
| Male | 18 | 22 | 5 | 45 |
| Race (NIH/OMB)(Participants) | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 4 |
| White | 27 | 24 | 9 | 60 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jan 2017, a primary completion of Aug 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solriamfetol
Disorders of Excessive Somnolence →